EMEA-001679-PIP01-14
Key facts
Active substance |
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0356/2022
|
PIP number |
EMEA-001679-PIP01-14
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Gilead Sciences International Ltd
|
Decision type |
PM: decision on the application for modification of an agreed PIP
|